Global Consensus on edentulous maxilla treatment

The recently published Global Consensus for Clinical Guidelines introduces a structured, evidence-based framework for managing one of the most complex challenges in implant dentistry: the edentulous maxilla.

In this interview, Prof. Frank Schwarz shares key insights into how these recommendations were developed, how they redefine treatment success, and what they mean for clinical decision-making in everyday practice.

1. What does this global consensus mean for clinicians and patients?

For me, this global consensus means that we now have the first truly global, structured, outcome-driven guideline for the rehabilitation of the edentulous maxilla. It is not just a scientific statement. It translates evidence into a practical clinical workflow with recommendations, decision trees, and checklists. For clinicians, that means greater clarity and greater consistency. For patients, it means that success is no longer defined only by implant survival or marginal bone levels, but also by comfort, function, speech, aesthetics, and quality of life. That is a major step toward internationally shared, patient-centered standards of care. 

2. What challenges drove the need for a global consensus on the edentulous maxilla?

The need came from two major challenges. First, the edentulous maxilla is one of the most complex scenarios in implant dentistry, because it requires balancing surgical feasibility, prosthetic design, anatomical limitations, complications, and long-term maintenance. Second, the literature has been dominated by clinician-reported outcomes, while patient-reported outcomes have remained underreported and poorly standardized. So the real challenge was not only to decide what works surgically, but to define success in a way that reflects what truly matters to patients in daily life. That is exactly why a global, structured guideline became necessary. 

3. How did global clinical and patient input shape the recommendations?

The recommendations were shaped by global input at several levels. The GCCG combined eight systematic reviews, six structured surveys, a three-round Delphi process, and final consensus voting by 105 delegates from 26 countries. The surveys included 472 clinicians from 63 countries, while the patient and cross-disciplinary expert panels focused specifically on expectations, treatment preferences, burdens, and priorities such as aesthetics, comfort, chewing function, speech, and psychosocial well-being. Importantly, the cross-disciplinary experts also included professionals from leading companies and foundations in implant dentistry and regenerative biomaterials. So this was not an ivory-tower exercise. It was truly multi-stakeholder and internationally grounded. 

4. Why are patient-reported outcomes essential when assessing regenerative success?

Patient-reported outcomes are essential because regenerative success cannot be judged only by what we see on a radiograph or by whether an implant survives. Patients experience treatment through pain, comfort, chewing ability, speech, aesthetics, confidence, and quality of life. The GCCG made this very clear by creating a Core Outcome Set with 34 critically important outcomes, including 10 patient-reported outcomes. It is also very telling that, in the review on alveolar ridge augmentation, PROs were reported in only 50% of included studies. So PROMs are not an accessory, they are the bridge between technical success and real patient benefit.

5. How critical is the choice of biomaterials for long-term bone regeneration in the edentulous maxilla?

The choice of biomaterials is highly critical for long-term bone regeneration, but the consensus approaches this in a mature and evidence-based way. It does not claim that one material fits every indication. What it does show is that bone substitutes are a valid grafting option, often with lower morbidity than autogenous harvesting, and that xenogeneic substitutes were the materials most frequently chosen by experts for lateral and crestal sinus lift procedures with simultaneous implant placement. That is highly relevant in the context of Geistlich Biomaterials, because it places evidence-based xenogeneic grafting in the center of routine clinical decision-making. It is also notable that the underlying review tables include several representative edentulous-maxilla protocols using Geistlich Bio-Oss® and Geistlich Bio-Gide®. 

6. How important is biomaterial predictability in building patient confidence and supporting shared decision-making?

Biomaterial predictability is fundamental because shared decision-making only works when the clinician can speak with confidence about stability, morbidity, treatment time, complication risk, and long-term maintenance. The GCCG repeatedly emphasizes shared decision-making, structured assessment, and real-world patient priorities. It also shows that clinicians continue to favor predictability and clinical feasibility over the rapid adoption of technologies that still lack robust long-term data. From that perspective, predictable biomaterials are not just a surgical convenience. They are part of how trust is built before treatment starts and how confidence is maintained afterward. 

Here, the close link between evidence, predictability, and patient confidence is highly relevant for established biomaterial solutions such as those from Geistlich.

7. Why are graft stability and membrane fixation critical for successful bone regeneration?

Graft stability and membrane fixation are critical because regeneration requires a protected and stable space. The GCCG specifically recommends secure fixation of barrier membranes in vertical ridge augmentation to maintain space and limit micromotion, thereby improving predictability and reducing exposure risk. The biological logic is straightforward: when the membrane is stable, the clot is stable, and that creates better conditions for bone formation. This is one of the clearest biomaterial-related messages of the entire consensus. It underlines that successful regeneration depends not only on the graft itself, but on the stability of the whole regenerative environment. 

8. How can appropriate biomaterial selection help clinicians manage complications more safely and effectively?

Appropriate biomaterial selection helps clinicians manage complications because the right material is not only about ideal-case regeneration. It is also about what happens when things become more difficult. The clearest example is Schneiderian membrane perforation. For small tears, the consensus supports repair with resorbable membranes and continuation of the procedure, and for moderate tears between 5 and 10 mm, collagen membranes are the preferred strategy. That is a major practical point. It means safer complication management, less disruption of treatment, and better preservation of predictability. It also highlights why handling characteristics and biological compatibility matter so much in everyday surgery. 

9. How do soft tissue grafting materials contribute to long-term peri-implant health and patient comfort?

Soft tissue grafting materials contribute substantially because full-arch success is not only a hard-tissue story. In patients with insufficient keratinized mucosa, the GCCG recommends soft tissue augmentation at implant placement or second-stage surgery to improve peri-implant health and facilitate oral hygiene. The evidence cited by the group also shows that these procedures can increase keratinized mucosa width and improve peri-implant health indices over time. From the patient perspective, this translates into better hygiene, more comfort, and a more maintainable restoration. 

Within this framework, the link between soft tissue management, long‑term maintenance, patient comfort, and the prevention of biological complications is particularly relevant for established soft tissue biomaterial solutions, such as those from Geistlich.

10. How did you feel when the consensus was finally published?

When the consensus was finally published, I felt proud, relieved, and grateful. Proud because this is the first global guideline for edentulous maxilla rehabilitation. Relieved because of an enormous international effort, including eight systematic reviews, six surveys, a three-round Delphi process, and voting by 105 delegates from 26 countries, was translated into something practical for daily clinical care. And grateful because it shows that our field can move toward internationally shared, patient-centered standards without losing scientific rigor or clinical realism. For me, that is the real achievement.